There are 805 resources available
59O - A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma
Presenter: Jianliang Yang
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Abstract
LBA6 - PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)
Presenter: Yi-Long Wu
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
LBA7 - Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05
Presenter: Myung-Ju Ahn
Session: Proffered Paper session: Thoracic malignancies
Resources:
Abstract
LBA1 - Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04)
Presenter: Changhoon Yoo
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
372O - Balstilimab (bal) alone or with zalifrelimab (zal) treatment for cervical cancer: An open-label, non-comparative, randomised, phase II trial
Presenter: Jusheng An
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
126O - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
Presenter: Thomas Yau
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
373O - First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study
Presenter: Danbo Wang
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
127O - Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Masatoshi Kudo
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
374O - The burden and trends of gynecological cancers in Asia from 1980 to 2021: A systematic analysis for the global burden of disease study 2021
Presenter: Run Miao
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
375O - DIsease burden and treatment pattern of Recurrent or advanced Endometrial cancer in Korea: A naTIONwide database (DIRECTION) study
Presenter: Hyun-woong Cho
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract